REDCARE PHARMACY NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.90 EUR | +4.43% |
|
-6.87% | -10.48% |
| Jan. 14 | Redcare Pharmacy NV: Europe's leading online pharmacy secures its position |  |
| Jan. 10 | REDCARE PHARMACY : Berenberg keeps its Buy rating | ZD |
Summary: Redcare Pharmacy NV
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: Redcare Pharmacy NV
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: Redcare Pharmacy NV
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings Chart: Redcare Pharmacy NV
Source: Surperformance
ESG chart: Redcare Pharmacy NV
Source: MSCI
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| - | 2.34B | ||||
| 11.32B | |||||
| 10.28B | |||||
| 6.71B | |||||
| 5.72B | |||||
| 4.61B | |||||
| 4.09B | |||||
| 4B | |||||
| 2.81B | |||||
| 2.7B | |||||
| Average | 5.46B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG MSCI
AAA
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
ESG
Environment
Social
Governance
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- RDC Stock
- Ratings Redcare Pharmacy NV